Byers Capital

Byers Capital is a single family office that specializes in direct, early-stage investments within the technology and biotechnology sectors. The firm acts as a Limited Partner in a select number of venture capital funds, but primarily focuses on direct investments. While most investments are made without outside limited partners, Byers Capital may raise capital from partners for specific portfolio companies as they mature and scale.

Founded in 2021 by Blake Byers, the firm leverages his extensive background in both venture capital and scientific research. Blake Byers previously served as a General Partner at GV (Google Ventures) for a decade, where he played a significant role in scaling the firm and made numerous successful early-stage investments. This experience provides Byers Capital with deep expertise to not only provide capital but also strategic guidance and industry connections to its portfolio companies.

Byers Capital's portfolio showcases a strong focus on cutting-edge innovation. Notable investments include Neuralink (brain-computer interfaces), NewLimit (longevity research), Factory (AI coding agents), SpaceX (multi-planetary exploration), Xai (AI for understanding the universe), Harmonic (mathematical superintelligence), Vial (clinical drug development), Xaira (AI drug discovery), Chai Discovery (in silico drug creation), and The Bot Co (AI-powered home robots). These investments span Seed, Series A, Series B, and Growth stages.

The firm is managed by Blake Byers, who is actively involved in building and investing in areas such as longevity, foundation models, AI drug development, AI robots, codegen, and brain-computer interfaces. His expertise and hands-on approach are central to Byers Capital's investment strategy and support for its portfolio companies.